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Purpose: Implantable cardioverter defibrillators (ICD) are the standard of care for primary prevention (PP) in patients with isch-
emic cardiomyopathy (ICM). However, PP ICD implantation is underused in Asian countries. This study investigated ICD im-
plantation rates and factors associated with appropriate PP ICD implants for ICM. 
Materials and Methods: In this prospective multicenter observational registry (ADVANCE-ICM registry), ICM patients who were 
eligible for PP ICD were screened and enrolled. Factors associated with appropriate ICD implantation, including hospital and 
clinical factors, were investigated.
Results: Of the 1453 ICM patients eligible for PP ICD [1111 male; median age, 71.0 (61.0–78.0) years], only 76 (5.2%) patients un-
derwent ICD implantation. Among hospital factors, a non-monetary incentive for referral (72.4% vs. 52.9%, p=0.001) and total 
hospital system score (6.0 vs. 5.0, p=0.013) were higher in the ICD than in the no-ICD group. In multivariate analysis, total hospi-
tal system score [odds ratio (OR), 1.28; 95% confidence interval (CI), 1.10–1.50] was an independent factor for predicting ICD im-
plantation, along with clinical factors, including high New York Heart Association class (≥III: OR, 7.29; 95% CI, 2.97–17.87) and 
younger age (<70 years: OR, 2.14; 95% CI, 1.30–3.53).
Conclusion: PP ICD implantation for ICM patients is underused in Korea. Hospital factors were important for improving PP ICD 
implantation rate, suggesting that new screening and referral systems for ICM patients would improve the PP ICD implantation 
rate (Clinical trial registration No. NCT03590925).
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INTRODUCTION
Heart failure (HF) patients with a reduced left ventricular 
ejection fraction (LVEF) are at increased risks for arrhythmic 
events and sudden cardiac death,1 and its prevention has 
been a clinical subject of interest for more than 25 years.2 Im-
plantable cardioverter defibrillator (ICD) device therapy has 
been shown to reduce the risk of sudden cardiac death and all-
cause mortality in primary3-5 and secondary prevention.6-9 The 
guidelines of the European Society of Cardiology10,11 and the 
American College of Cardiology Foundation/American Heart 
Association12,13 give class 1 recommendations for implanta-
tion of ICD devices for primary prevention (PP) in symptom-
atic [New York Heart Association (NYHA) functional class II, 
III] HF patients with a LVEF ≤35% despite optimal medical 
therapy for more than 3 months.
Randomized clinical trials have shown a mortality benefit 
from PP ICD in patients at high risk of sudden cardiac death.3,4,14-16 
Indications for PP ICD implantation in Korea were published 
in 2008 and revised in 2016. The Korean indication guidelines 
for PP ICD implantation in ischemic cardiomyopathy (ICM) 
are as follows: 1) LVEF ≤30% [at least 40 days post-myocardial 
infarction (MI)]; 2) LVEF 31–35%, NYHA class II, III (at least 40 
days post-MI); and 3) LVEF ≤40%, non-sustained ventricular 
tachycardia, and inducible ventricular fibrillation or sustained 
ventricular tachycardia on an electrophysiological study (at 
least 40 days post-MI). Despite these well-publicized guide-
lines, implant rates are lower than national targets, and PP 
ICD accounts for only a minority of implants in Korea.
Despite extensive clinical trial evidence and recommenda-
tions in national guidelines, treatment guidelines are adopted 
slowly in Asian countries and applied inconsistently.17 Poor 
guideline adherence often fails to lead to improvements in pa-
tient care quality and outcomes.18-24 The reasons for low PP im-
plant rates are likely to be multifactorial and include a lack of 
physician knowledge (particularly non-implanting cardiolo-
gists); failure to implement guidelines; failure to screen patients 
and collect relevant data, such as LVEF; a lack of financial re-
sources or available implanting cardiologists; age, sex, or race 
bias; or even patient refusal to accept therapy. For hospitalized 
HF patients and outpatients, gaps, variations, and disparities 
between evidence-based guideline recommendations and 
actual treatments provided have been documented.18-24 The 
underuse of ICD and cardiac resynchronization therapy with 
a defibrillator is an issue in Asian countries.25-29 Collaboration 
between interventionists and electrophysiologists may facili-
tate ICD implantation in eligible patients. This study investi-
gated ICD implantation rates and factors associated with appro-




The Evaluation of the Improvement of Primary Prevention in 
Ischemic Cardiomyopathy patients using new screening and 
referral systems (ADVANCE-ICM) is a prospective multicenter 
observational study of patients aged >18 years and <90 years 
with ICM and an LVEF ≤40% who were attending any of the 12 
tertiary centers encompassing all geographical regions of Ko-
rea. The study enrollment period started in July 2018 and will 
end in June 2021.
The aim of the ADVANCE-ICM study is to evaluate the ef-
fect of the new screening and referral systems to improve PP 
in ICM patients through a prospective, non-randomized, non-
blinded, observational, multicenter design. Patients were en-
rolled in this study if they were eligible for ICD implantation for 
PP with ICM and offered adequate treatment regardless of ac-
tual ICD implantation. Patients who underwent ICD implanta-
tion for PP of sudden cardiac death with severe LV dysfunction 
due to ICM during follow-up period were evaluated. Indica-
tions for ICD implantation for PP were according to the 2016 
revised Korean indication guidelines. The data collection was 
usually conducted by personnel with no clinical activity as-
signed to the project. The data were entered into a common 
electronic database that limits inconsistencies and errors and 
provides online help for key variables. The study staff at each 
center could see their own center’s data and the data from all 
other participating centers. 
The study was approved by the ethics committees of each 
center, and all patients provided informed consent for their 
inclusion (IRB number: 4-2018-0075). The study complied 
with the ethical rules of the Declaration of Helsinki as a state-
ment of ethical principles for medical research involving hu-
man subjects by the World Medical Association. We followed 
all ethical, scientific, and medical standards that protect the 
rights of participants and required informed consent from all 
study participants and review and approval of study protocols, 
including patient information forms, from respective ethics 
committees: Severance Hospital, Seoul National University 
Hospital, Korea University Medical Center, Daegu Catholic 
University Medical Center, Ewha Womans University Medical 
Center, Kyung Hee University Hospital, Inha University Hos-
pital, Gangnam Severance Hospital, CHA Bundang Medical 
Center, Seoul St. Mary’s Hospital, Seoul National University 
Bundang Hospital, and Wonju Severance Hospital. This study 
was registered at ClinicalTrials.gov (NCT03590925). 
Among the 12 hospitals, three started enrollment late be-
cause of delayed IRB approval or late participation in this study. 
For accurate results, we analyzed the data of patients from 
nine hospitals. A total of 1453 ICM patients with PP ICD indi-
cations were enrolled in the ADVANCE-ICM registry from July 
2018 to February 2020. Among them, ICD was implanted in 76 
patients (ICD group), but not in 1377 patients (no-ICD group).
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Patient factors 
Age; sex; body mass index; medical histories of hypertension, 
diabetes mellitus, valvular heart disease, congestive HF, pe-
ripheral arterial occlusive disease (PAOD), stroke or transient 
ischemic attack, dyslipidemia, chronic kidney disease, malig-
nancy, and bleeding; NYHA class; prescribed medication; and 
echocardiographic parameters, such as LVEF, left atrial (LA) 
anteroposterior diameter, LA volume index, and E/Em, were 
obtained from medical records at the time of enrollment. 
Hospital factors 
Hospital factors of each center associated with ICD implanta-
tion were evaluated by a questionnaire. Total hospital system 
score was defined as the sum of the number of applied systems, 
including multidisciplinary conference, non-monetary incen-
tive for referral, automated notice system, patient education 
system, patient brochure, HF clinic, and ICD check-up clinic. 
Non-monetary incentive for referral was defined as a reward 
system for encouraging physicians to refer patients to electro-
physiology doctors. The term ‘non-monetary incentive’ in this 
paper does not mean economic rewards or compensation, but 
a recognition of medical performance or clinical achievement. 
The automated notice system was a computerized system that 
automatically shows a pop-up memo to physicians when pa-
tients who are eligible for ICD implantation visit the outpa-
tient clinic. 
Statistical analysis
Continuous variables are presented as medians [interquartile 
range (IQR)] for non-normally distributed value, and categor-
ical variables are shown as numbers and percentages in each 
group. Continuous and categorical variables were compared 
using the Wilcoxon rank-sum test and Fisher’s exact test, re-
spectively. To investigate factors associated with appropriate 
ICD implantation, univariate and multivariate logistic regres-
sion were employed, and odds ratio (OR), 95% confidence in-
tervals (CI), and p values were determined. Since system fac-
tors have multicollinearity, total hospital system score was used 
as the system factor in the multivariate logistic regression analy-
sis. Additional analyses to elucidate characteristics among cen-
ters were performed based on a questionnaire and informa-
tion of each center using Kruskal-Wallis test and Fisher’s exact 
tests. Two-sided p values <0.05 were considered statistically sig-
nificant. The Statistical Package for the Social Sciences version 
25.0 for Windows (IBM Corporation, Armonk, NY, USA) and R 
software version 3.6.2 (The R foundation for Statistical Com-
puting, Vienna, Austria) were employed in the data analysis.
RESULTS
Baseline clinical characteristics    
A total of 1453 ICM patients [1111 male, median age 71.0 (61.0–
78.0) years] eligible for PP ICD were enrolled in the ADVANCE-
ICM registry from July 2018 to February 2020. Among them, 
ICD was implanted in 76 patients during 11 (IQR, 7–12) months 
of follow-up. The patients in the ICD group were significantly 
younger (67.0 years vs. 71.0 years, p=0.002), had a higher (≥III) 
NYHA functional class (10.5% vs. 2.8%, p<0.001), had a lower 
LVEF (29.0% vs. 31.0%, p<0.001), and were taking more angio-
tensin converting enzyme inhibitor (ACEi)/angiotensin recep-
tor antagonist (ARB) and antiarrhythmic agents than patients 
in the no-ICD group (Table 1).
Hospital factors
The detailed applied systems for advancing ICD implantation 
in each center and the characteristics of the nine tertiary cen-
ters, including hospital bed supply, number of electrophysiol-
ogists, absolute ICD implantation number, ICD implantation 
rate, and referral rate for ICD implantation from other parts, 
are shown in Supplementary Table 1 (only online). 
To elucidate the effect of hospital size on ICD implantation, 
the centers were divided into three groups according to the 
number of hospital beds as a marker of hospital size (group 1, 
≥1200 beds; group 2, ≥850 but <1200 beds; and group 3, <850 
beds). Groups 1 and 2 had significantly higher total hospital 
system scores than group 3 (group 1 vs. group 3, p=0.046; group 
2 vs. group 3, p=0.043) (Fig. 1A). The absolute number of ICD 
implantations was higher in group 1 than groups 2 and 3 (group 
1 vs. group 2, p=0.043; group 1 vs. group 3, p=0.046) (Fig. 1B). 
However, ICD implantation rate did not differ significantly 
among the three groups (Fig. 1C). To investigate factors affect-
ing the ICD implantation rate in the larger (group 1) and small-
er (group 3) centers, the centers’ characteristics were reviewed. 
A higher referral rate was noted in centers with higher ICD im-
plantation rates (Supplementary Table 1, only online). To eval-
uate the effects of the referral rate, centers were divided into 
two groups according to their referral rates (group A, ≥30%; 
group B, <30%). Group A had significantly higher total hospi-
tal system scores than group B (group A vs. group B; p=0.032) 
(Fig. 2A). Group A also had a significantly higher number of 
absolute ICD implantations than group B (group A vs. group B; 
p=0.032) (Fig. 2B). However, ICD implantation rate did not dif-
fer between the two groups (group A vs. group B; p>0.999) (Fig. 
2C). Instead, additional analysis of the association between 
individual hospital factors with ICD implantation rate re-
vealed that ICD implantation rates were higher in hospitals 
that applied non-monetary incentives for referral systems than 
hospitals that did not (p=0.016) (Fig. 3).
Table 2 shows a comparison hospital system factors between 
the ICD and no-ICD groups. Among hospital factors, a non-
monetary incentive for referral (72.4% vs. 52.9%; p=0.001) and 
total hospital system score (6.0 vs. 5.0; p=0.013) were higher in 
the ICD group than in the no-ICD group (Table 2). 
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Factors associated with appropriate ICD implantation
In univariate analysis, age <70 years, absence of a history of 
PAOD; taking ACEi/ARB, beta blocker, or antiarrhythmic agents; 
severe NYHA functional class (III and IV) were significantly 
associated with appropriate ICD implantation [Table 3 and 
Supplementary Table 2 (only online)]. Due to multicollineari-
ty among the applied systems, total hospital system score was 
used to represent hospital systems, and the score was signifi-
cantly high in the ICD group. The univariate analysis results of 
all variables are shown in Supplementary Table 2 (only on-
line).
Multivariate analysis was performed with adjustment for age 
<70 years; presence of PAOD; NYHA functional class (III and 
IV); taking ACEi/ARB, beta blocker, and antiarrhythmic agents; 
and total hospital system score. Total hospital system score 
(OR, 1.28; 95% CI, 1.10–1.50) was an independent factor pre-
dictive of ICD implantation with clinical factors, including high 
NYHA class (≥III: OR, 7.29; 95% CI, 2.97–17.87) and younger 
age (<70 years: OR, 2.14; 95% CI, 1.30–3.53) (Table 3). 
DISCUSSION
Main findings
The main findings of the present study are as follows: 1) the 
ICD implantation rate for PP for ICM in nine tertiary centers in 
Korea was only 5.23%; 2) age <70 years, absence of history of 
PAOD, taking antiarrhythmic agents, NYHA functional class 
III and IV, and high total hospital system scores were associat-
ed with appropriate ICD implantation; and 3) larger centers 
Table 1. Baseline Clinical and Echocardiographic Parameters in the ICD and No-ICD Groups
All subjects (n=1453) ICD group (n=76) No-ICD group (n=1377)  p value
Age (yr) 71.0 (61.0–78.0) 67.0 (59.0–72.5) 71.0 (61.0–78.0) 0.002
Male 1111 (76.5) 60 (78.9) 1051 (76.3) 0.700
BMI (kg/m2) 23.5 (21.3–25.7) 24.4 (21.6–26.0) 23.5 (21.3–25.7) 0.076
Hypertension 942 (64.8) 50 (65.8) 892 (64.8) 0.955
Diabetes mellitus 720 (49.6) 37 (48.7) 683 (49.6) 0.970
Valvular heart disease 275 (18.9) 11 (14.5) 264 (19.2) 0.386
Congestive heart failure 1305 (89.8) 68 (89.5) 1237 (89.8) >0.999
PAOD 847 (58.3) 36 (47.4) 811 (58.9) 0.062
Stroke/TIA 195 (13.4) 8 (10.5) 187 (13.6) 0.557
Dyslipidemia 881 (60.6) 39 (51.3) 842 (61.1) 0.112
Chronic kidney disease 351 (24.2) 19 (25.0) 332 (24.1) 0.969
Malignancy 83 (5.7) 3 (3.9) 80 (5.8) 0.669
Bleeding history 47 (3.2) 3 (3.9) 44 (3.2) 0.978
NYHA functional class
Class I, II 1407 (96.8) 68 (89.5) 1339 (97.3) <0.001
Class III, IV 46 (3.2) 8 (10.5) 38 (2.8) <0.001
LVEF (%) 31.0 (26.0–35.0) 29.0 (25.0–32.0) 31.0 (26.0–35.0) <0.001
LA AP diameter (mm) 44.0 (39.0–49.0) 43.9 (36.3–57.6) 43.7 (32.5–56.8) 0.266
LA volume index (mL/m2) 43.8 (32.8–56.8) 45.0 (40.0–49.0) 44.0 (39.0–49.0) 0.644
E/Em 15.5 (11.4–22.5) 14.0 (10.5–21.7) 15.5 (11.5–22.5) 0.301
Medication
ACEi/ARB 1119 (81.3) 68 (91.9) 1051 (80.7) 0.025
Beta blocker 1096 (79.7) 66 (89.2) 1030 (79.1) 0.052
Aldosterone antagonist 684 (49.7) 44 (59.5) 640 (49.2) 0.108
Anticoagulant 301 (21.9) 19 (25.7) 283 (21.7) 0.514
Diuretics 753 (54.7) 48 (64.9) 705 (54.1) 0.093
Statin 1095 (79.6) 63 (85.1) 1032 (79.3) 0.284
Antiplatelet 1130 (82.1) 56 (75.7) 1074 (82.5) 0.183
Antiarrhythmic agent 65 (4.7) 8 (10.8) 57 (4.4) 0.024
CCB 152 (11.0) 8 (10.8) 144 (11.1) >0.999
ACEi, angiotensin converting enzyme inhibitor; AP, anteroposterior; ARB, aldosterone receptor blocker; BMI, body mass index; CCB, calcium channel blocker; E/
Em, ratio of mitral valve inflow and tissue doppler; ICD, implantable cardioverter defibrillator; LA, left atrial; LVEF, left ventricular ejection fraction; NYHA, New 
York Heart Association; PAOD, peripheral arterial occlusive disease; TIA, transient ischemic attack.
Values are presented as a median [Q1–Q3 quartiles (25th and 75th percentiles)] or number (%).
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Fig. 1. Associations between center size and total hospital system score, 
ICD implantation number, and ICD implantation rate. (A) Large centers 
(groups 1 and 2) applied more systems for improving ICD implantation 
than relatively small centers (group 3). (B) Large centers (group 1) also 
implanted higher numbers of ICDs than smaller centers (group 2 and 3). 
(C) However, ICD implantation rate did not differ according to center size. 
ICD, implantable cardioverter defibrillator.
Fig. 2. Associations between referral rate and total hospital system 
score, ICD implantation number, and ICD implantation rate. (A) Centers 
with a high referral rate from other departments (group A) applied more 
systems than centers with a low referral rate (group B). (B) Further-
more, centers with a high referral rate (group A) implanted more ICD 
implantations than centers with a low referral rate (group B). (C) How-
ever, ICD implantation rate did not differ according to referral rate. ICD, 
implantable cardioverter defibrillator.
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and centers with higher referral rates applied more hospital 
systems for improving ICD implantation and implanted more 
absolute numbers of PP ICDs. However, implantation rate did 
not differ significantly according to the sizes or referral rates 
for each hospital. Instead, implantation rates differed signifi-
cantly according to the application of a non-monetary incen-
tive for referral systems.
Discordant practice in PP ICD 
Despite the existence of evidence-based and well-established 
national guidelines, PP ICD implant rates vary among coun-
tries and are low in Asian countries.17,29 Previous studies report-
ed that PP ICD implantation rates for eligible patients were 
10%, 60%, and 5% in Sweden, US, and an Asian country, re-
spectively.25,26,29 The present study showed that only 5.23% of 
patients who were eligible for PP ICD were treated with ICDs. 
We could not evaluate whether electrophysiology study was 
performed in patients whose LVEF was over 35% according to 
guidelines because of the multicenter study design. Instead, 
Table 2. Baseline Hospital Factors Related to ICD Implantation in the ICD and No-ICD Groups
All subjects (n=1453) ICD group (n=76) No-ICD group (n=1377)  p value
Multidisciplinary conference 1012 (69.6) 57 (75.0) 955 (69.4) 0.361
Non-monetary incentive for referral 784 (54.0) 55 (72.4) 729 (52.9) 0.001
Automated notice system 957 (65.9) 57 (75.0) 900 (65.4) 0.109
Patient education system 1316 (90.6) 70 (92.1) 1246 (90.5) 0.788
Patient brochure 981 (67.5) 58 (76.3) 923 (67.0) 0.119
Heart failure clinic 1158 (79.7) 62 (81.6) 1096 (79.6) 0.785
ICD check-up clinic 1315 (90.5) 66 (86.8) 1249 (90.7) 0.359
Total hospital system score* 5.0 (4.0–7.0) 6.0 (5.0–7.0) 5.0 (4.0–7.0) 0.013
ICD, implantable cardioverter defibrillator.
Values are presented as a median [Q1–Q3 quartiles (25th and 75th percentiles)] or number (%).
*A sum of the number of applied systems, including multidisciplinary conference, non-monetary incentive for referral, automated notice system, patient educa-
tion system, patient brochure, heart failure clinic, and ICD check-up clinic.
Table 3. Univariate and Multivariate Logistic Regression Analyses of Patient and System Score Factors Affecting ICD Implantation
Univariate Multivariate*
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age <70 1.92 (1.19–3.08)   0.007 2.14 (1.30–3.53) 0.003
PAOD 0.63 (0.40–1.00)   0.049 0.55 (0.34–0.91) 0.019
NYHA class ≥3 4.15 (1.86–9.23) <0.001   7.29 (2.97–17.87) <0.001
LVEF <25% 1.64 (0.95–2.85)   0.076
Medication
ACEi/ARB 2.71 (1.16–6.31)   0.021 1.95 (0.80–4.77) 0.141
Beta blocker 2.18 (1.03–4.59)   0.041 1.93 (0.89–4.22) 0.098
Diuretics 1.56 (0.96–2.55)   0.074
Antiarrhythmic agent 2.65 (1.21–5.78)   0.014 3.77 (1.66–8.60) 0.002
Total hospital system score† 1.17 (1.01–1.35)   0.038 1.28 (1.10–1.50) 0.002
ACEi, angiotensin converting enzyme inhibitor; ARB, aldosterone receptor blocker; CI, confidence interval; ICD, implantable cardioverter defibrillator; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association; PAOD, peripheral arterial occlusive disease.
*Odds ratio was adjusted for age <70 years, presence of PAOD, NYHA functional class (III and IV), taking ACEi/ARB, beta blocker, and antiarrhythmic agent, and 
total hospital system score, †A sum of the number of applied systems, including multidisciplinary conference, non-monetary incentive for referral, automated no-
































Fig. 3. Association between non-monetary incentive systems and ICD 
implantation rate. ICD implantation rates were higher in centers that 
applied non-monetary incentive systems than in those that did not. ICD, 
implantable cardioverter defibrillator.
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we additionally evaluated ICD implantation rates in patients 
whose LVEF was lower than 35%, and therein, the ICD implan-
tation rate was 5.31%. These centers have better established 
electrophysiology laboratories than relatively small hospitals, 
indicating that the implantation rate of PP ICD in community 
settings could be much lower. Previous studies explained that 
the discordant practice in PP ICD was largely influenced by 
referral failure from general cardiologists to electrophysiology 
cardiologists in the UK.30,31 Since health care systems differ 
among countries, a direct comparison of the results of the pres-
ent study with those of other studies is impossible. However, 
the present study revealed that the application of hospital sys-
tems for referral pathway, such as a non-monetary incentive 
system for referral, was associated with high ICD implantation 
rates, and this result could indicate the importance of referral 
pathways for appropriate PP ICD implantation in ICM pa-
tients, in line with previous studies.
Characteristics of patients with appropriate PP ICD
Previous trials have described an underutilization of ICD im-
plantation in women and ethnic minorities.32 However, the re-
sults of the present study showed no sex-based differences be-
tween the ICD and no-ICD groups. We did not evaluate ethnic 
factors because there is fundamentally no ethnic difference 
among people in Korea. Limited data are available about ICD 
implantation in older patients because several trials excluded 
patients 80 years or older.33,34 A previous questionnaire survey 
also revealed that physicians tended not to follow guidelines 
in patients who are older and have comorbidities.30 In accor-
dance with previous studies, the present study revealed that age 
<70 years and less PAOD were factors associated with appro-
priate PP ICD implantation. Physicians may hesitate to refer 
older patients for ICD implantation due to limited evidence. 
Furthermore, since older patients and those with PAOD might 
have other comorbidities, physicians may have difficulty choos-
ing additional procedures with consideration of the risks and 
benefits. A previous study reported that, among HF patients 
with indications for ICD, there was a higher ICD implantation 
rate in patients who were treated with guideline-based opti-
mal medical therapy.21 However, the present study demon-
strated that taking HF medications was not associated with ap-
propriate ICD implantation. The present study revealed that 
taking antiarrhythmic agents and having a higher NYHA func-
tional class (III, IV) independently affected appropriate ICD 
implantation. Patients with more severe symptoms or deterio-
rated cardiac function should be considered at high risk for 
future arrhythmic events.
Systems for ICD implantation and characteristics of 
each center
Previous studies have reported that underutilization of PP 
ICD implantation could be the result of a lack of knowledge 
and complex guideline criteria. Therefore, an automated, com-
puterized screening system could help countries overcome 
those problems.30 In the present study, a total hospital system 
score and a non-monetary incentive for referral were associat-
ed with improved appropriate ICD implantation. An automated 
notice system might help physicians decrease the risk of over-
looking ICD-eligible patients during follow up in outpatient 
clinics. A non-monetary incentive for referral can motivate 
physicians and could be an effective way to improve the refer-
ral pathway. The results of this study showed that a high rate 
of system application, regardless of composition, was a signif-
icant independent factor for ICD implantation. This result in-
dicates that both system type and harmony might be impor-
tant for improving PP ICD.
The present study showed that, although larger hospital had 
more systems for improving ICD implantation and more ICDs 
were implanted in large volume centers, the implantation rate 
was not significantly associated with hospital size. Previous 
studies have reported that barriers to the referral pathway and 
non-referral were the most common factors contributing to el-
igible patients not being treated with ICD.28,31,35 However, the 
present study revealed that the ICD implantation rates of each 
hospital did not differ according to referral rates. Referral rates 
in this study were assessed via questionnaires with multiple 
choice questions. Therefore, the cutoff for a referral rate of 30% 
in the analysis was not an exact determinant for a high or low 
referral rate. This could be the reason for the non-statistical 
significance between referral rate and ICD implantation rate. 
Instead, the number of applied hospital systems and the non-
monetary incentive for referral, which were designed for bet-
ter screening and referral pathways, showed a beneficial in-
fluence on appropriate PP ICD treatment. This results could 
emphasize the need for better screening and referral path-
ways for appropriate PP ICD implantation. To our knowledge, 
this is the first study to investigate the usefulness of hospital 
systems for improving appropriate ICD implantation in mul-
tiple tertiary centers.
Study limitations
There are several limitations to this study. First, although it was 
prospective and enrolled a large population, the follow-up pe-
riod (median 10 months) was relatively short. In Korea, pa-
tients usually visit the outpatient clinic every 6 months, so the 
follow-up period of this study could be inadequate for evalu-
ating the benefit of new applied systems. Furthermore, ICD 
implantation rate could be underestimated with the short fol-
low-up duration because there could be a delay in procedures 
for several reasons, even though physicians properly recom-
mended PP-ICD according to set guidelines. Second, since 
some systems were usually applied together, analysis of the 
usefulness of each system was limited due to multicollineari-
ty. We tried to correct for this limitation by using a new vari-
able of total hospital system score. Third, the timing of the ap-
plication of hospital factors varied, and the actual application 
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of the systems to each patient could not be traced. This could 
obscure the effect of hospital systems. However, since most 
hospital factors were applied through established hospital sys-
tems and performed by physicians, we believed that a substan-
tial portion of hospital factors would be applied to each patient.
Conclusion
PP ICD implantation for ICM is underused in Korea. Hospital 
factors appear to contribute to improving PP ICD implanta-
tion rates, suggesting that new screening and referral systems 
for ICM patients would help improve PP ICD implantation 
rates.
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